The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Mutational Activation of the K-ras Oncogene
Abstract
To define the role of cellular oncogenes in human cancers, we studied the prevalence of mutational activation of ras oncogenes in untreated non-small-cell lung cancer. Genomic DNA was extracted from 39 tumor specimens obtained by thoracotomy and was examined for activating point mutations in codons 12, 13, and 61 of the H-ras, K-ras, and N-ras genes. A novel, highly sensitive assay based on oligonucleotide hybridization following an in vitro amplification step was employed. The K-ras gene was found to be activated by point mutations in codon 12 in 5 of 10 adenocarcinomas. Two of these tumors were less than 2 cm in size and had not metastasized. No ras gene mutations were observed in 15 squamous-cell carcinomas, 10 large-cell carcinomas, 1 carcinoid, 2 metastatic adenocarcinomas from primary tumors outside the lung, and 1 small-cell carcinoma. An approximately 20-fold amplification of the unmutated K-ras gene was observed in a tumor that proved to be a solitary lung metastasis of a rectal carcinoma. We conclude that mutational K-ras activation may be an important early event in the pathogenesis of adenocarcinoma of the lung but that amplification of ras genes or mutational activation of H-ras or N-ras does not play a major part in non-small-cell lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of specific sequences among DNA fragments separated by gel electrophoresis
Southern, E. M. (1975) · Journal of Molecular Biology · doi:10.1016/s0022-2836(75)80083-0 · Cited by 32,249
Prevalence of ras gene mutations in human colorectal cancers
Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., van Boom, J. H., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860
Self-citationDetection of high incidence of K-ras oncogenes during human colon tumorigenesis
Forrester, K., Almoguera, C., Han, K., Grizzle, W. E., & Perucho, M. (1987) · Nature · doi:10.1038/327298a0 · Cited by 1,061
Amplification and expression of the c-myc oncogene in human lung cancer cell lines
Little, C. D., Nau, M. M., Carney, D. N., Gazdar, A. F., & Minna, J. D. (1983) · Nature · doi:10.1038/306194a0 · Cited by 920
Assay for nanogram quantities of DNA in cellular homogenates
Brunk, C. F., Jones, K. C., & James, T. W. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90690-0 · Cited by 906
Heisterkamp, N., Stephenson, J. R., Groffen, J., Hansen, P. F., de Klein, A., Bartram, C. R., & Grosveld, G. (1983) · Nature · doi:10.1038/306239a0 · Cited by 842
Nicolson, G. L. (1987) · PubMed · Cited by 502
Goldfarb, M., Shimizu, K., Perucho, M., & Wigler, M. (1982) · Nature · doi:10.1038/296404a0 · Cited by 484
Hall, A., Marshall, C. J., Spurr, N. K., & Weiss, R. A. (1983) · Nature · doi:10.1038/303396a0 · Cited by 442
Santos, E., Martin-Zanca, D., Reddy, E. P., Pierotti, M. A., Della Porta, G., & Barbacid, M. (1984) · Science · doi:10.1126/science.6695174 · Cited by 418
Research works printed but not linked: 11
- Nicolson, 1987, Cancer Res, 47, 1473
- 10.1126/science.6691135 · doi:10.1126/science.6691135
- Barbacid M. Human oncogenes. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Important advances in oncology 1986. Philadelphia: J.B. Lippincott, 1986:3–22.
- Sistonen, 1986, Ann Clin Res, 18, 297
- 10.1093/carcin/7.11.1931 · doi:10.1093/carcin/7.11.1931
- Sobin, 1982, Cancer Detect Prev, 5, 391
- Janssen, 1985, Cancer Res, 45, 3262
- Carman, 1984, J Clin Oncol, 2, 16, 10.1200/JCO.1984.2.1.16 · doi:10.1200/jco.1984.2.1.16
- Kurzrock, 1986, Cancer Res, 46, 1530
- Frazier, 1986, Int J Radiat Biol, 49, 542
- Furth, 1987, Oncogene, 1, 47
Cited by
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Gene-expression profiles predict survival of patients with lung adenocarcinoma
Beer, D. G., Kardia, S. L. R., Huang, C.-C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., et al. (2002) · Nature Medicine · doi:10.1038/nm733 · Cited by 2,025
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
Characterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105
K-ras Oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung
Slebos, R. J. C., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J. L. M., Wagenaar, S. S., Vanderschueren, R. G. J. R. A., van Zandwijk, N., Mooi, W. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230902 · Cited by 809
Self-citationThe ras gene family and human carcinogenesis
Bos, J. L. (1988) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/0165-1110(88)90004-8 · Cited by 782
Self-citationEttinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Demmy, T. L., Ganti, A. K. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0056 · Cited by 730
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Dearden, S., Stevens, J., Wu, Y.-L., & Blowers, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt205 · Cited by 646
Dogan, S., Shen, R., Ang, D. C., Johnson, M. L., D'Angelo, S. P., Paik, P. K., Brzostowski, E. B., Riely, G. J., Kris, M. G., Zakowski, M. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3265 · Cited by 639
“Although KRASmutations were identified in lung cancer more than 2 decades ago (9, 10), the clinical importance of KRAS mutation status became apparent only relatively”
BackgroundFrequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0646 · Cited by 578
Biomarker development in the precision medicine era: lung cancer as a case study
Vargas, A. J., & Harris, C. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.56 · Cited by 556
KRAS Mutations in Non-Small Cell Lung Cancer
Riely, G. J., Marks, J., & Pao, W. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-107lc · Cited by 550
DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
Zheng, Z., Chen, T., Li, X., Haura, E., Sharma, A., & Bepler, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065411 · Cited by 462
Second Lung Cancers in Patients After Treatment for an Initial Lung Cancer
Johnson, B. E. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1335 · Cited by 393
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
Reck, M., Carbone, D. P., Garassino, M., & Barlesi, F. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.001 · Cited by 326
You, M., Candrian, U., Maronpot, R. R., Stoner, G. D., & Anderson, M. W. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.9.3070 · Cited by 336
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301
Culture and transformation of human airway epithelial cells
Gruenert, D. C., Finkbeiner, W. E., & Widdicombe, J. H. (1995) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1995.268.3.l347 · Cited by 293
Shepherd, F. A., Domerg, C., Hainaut, P., Jänne, P. A., Pignon, J.-P., Graziano, S., Douillard, J.-Y., Brambilla, E., Le Chevalier, T., Seymour, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.1390 · Cited by 293
Oncogenes, Growth Factors, and Signal Transduction
Flier, J. S., Underhill, L. H., Druker, B. J., Mamon, H. J., & Roberts, T. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212007 · Cited by 292
High frequency of Ki‐ras codon 12 mutations in pancreatic adenocarcinomas
Grünewald, K., Lyons, J., Fröhlich, A., Feichtinger, H., Weger, R. A., Schwab, G., Janssen, J. W. G., & Bartram, C. R. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430614 · Cited by 290
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
van 't Veer, L. J., Burgering, B. M., Versteeg, R., Boot, A. J., Ruiter, D. J., Osanto, S., Schrier, P. I., & Bos, J. L. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.7.3114 · Cited by 283
Self-citationSchmid, K., Oehl, N., Wrba, F., Pirker, R., Pirker, C., & Filipits, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0089 · Cited by 262
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
Johnson, M. L., Sima, C. S., Chaft, J., Paik, P. K., Pao, W., Kris, M. G., Ladanyi, M., & Riely, G. J. (2013) · Cancer · doi:10.1002/cncr.27730 · Cited by 166
RAS mutations in human cancers: Roles in precision medicine
Murugan, A. K., Grieco, M., & Tsuchida, N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.007 · Cited by 146
Shepherd, F. A., Lacas, B., Le Teuff, G., Hainaut, P., Jänne, P. A., Pignon, J.-P., Le Chevalier, T., Seymour, L., Douillard, J.-Y., Graziano, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2893 · Cited by 124
Current therapy of KRAS-mutant lung cancer
Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115
“As in other malignancies, KRAS mutation was first reported to be a negative prognostic factor in NSCLC in the 1980s [24, 25].”
BackgroundEfficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
Passiglia, F., Cappuzzo, F., Alabiso, O., Bettini, A. C., Bidoli, P., Chiari, R., Defferrari, C., Delmonte, A., Finocchiaro, G., Francini, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0234-3 · Cited by 81
Biomarkers in Lung Cancer: From Early Detection to Novel Therapeutics and Decision Making
Scott, A., & Salgia, R. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.6.577 · Cited by 59
Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
Zocche, D. M., Ramirez, C., Fontao, F. M., Costa, L. D., & Redal, M. A. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00116 · Cited by 50
Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer
Rosellini, P., Amintas, S., Caumont, C., Veillon, R., Galland-Girodet, S., Cuguillière, A., Nguyen, L., Domblides, C., Gouverneur, A., Merlio, J.-P., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.026 · Cited by 44
Efforts to Develop KRAS Inhibitors
Holderfield, M. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031864 · Cited by 43
Ghimessy, Á. K., Gellert, Á., Schlegl, E., Hegedus, B., Raso, E., Barbai, T., Timar, J., Ostoros, G., Megyesfalvi, Z., Gieszer, B., et al. (2019) · Cancers · doi:10.3390/cancers11101514 · Cited by 27
Metadata
- Authors
- Rodenhuis, S., van de Wetering, M. L., Mooi, W. J., Evers, S. G., van Zandwijk, N., & Bos, J. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1987-10-08
- Volume
- 317
- Issue
- 15
- Pages
- 929-935
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2320138981
- Cited by
- 536
- References
- 31
- FWCI
- 46.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.